Need help choosing the right code?
Ask CasePilot about procedures, modifiers, bundling, and coding guidance.
Try CasePilot© Copyright 2026 American Medical Association. All rights reserved.
The CPT® Code 82145 refers to laboratory testing specifically for the presence of amphetamine or methamphetamine in biological samples. These substances are classified as psychostimulant drugs belonging to the phenethylamine class, which are known for their stimulating effects on the central nervous system. The testing can be conducted on various types of specimens, including urine, blood, or meconium stool, particularly in newborn infants. Amphetamines and methamphetamines are often associated with recreational use and are sometimes misused for enhancing athletic performance. However, they also have legitimate medical applications, as they may be prescribed to manage symptoms in individuals diagnosed with Attention Deficit Disorder (ADD) and Attention Deficit Hyperactivity Disorder (ADHD). The laboratory analysis typically involves obtaining a sample from the patient, which is then subjected to a sophisticated testing method known as quantitative liquid chromatography-tandem mass spectrometry. This method allows for precise measurement and identification of the substances in the sample, ensuring accurate results for clinical or forensic purposes.
© Copyright 2026 Coding Ahead. All rights reserved.
The laboratory testing for amphetamine or methamphetamine is indicated in various clinical scenarios, particularly when there is a suspicion of substance use or abuse. The following conditions may warrant such testing:
The procedure for testing amphetamine or methamphetamine involves several key steps to ensure accurate and reliable results. The following outlines the procedural steps involved:
Post-procedure care primarily involves the interpretation of test results and any necessary follow-up actions based on those results. If the test indicates the presence of amphetamines or methamphetamines, further evaluation may be required to assess the implications for the patient's health or treatment plan. In cases of newborn screening, appropriate interventions may be initiated to address any identified issues related to maternal substance use. Additionally, healthcare providers may need to discuss the results with the patient or their guardians, providing guidance on the next steps, which may include counseling, further testing, or adjustments to treatment plans.
| Short Descr | ASSAY OF AMPHETAMINES | Medium Descr | AMPHETAMINE/METHAMPHETAMINE | Long Descr | Amphetamine or methamphetamine | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 9 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | APC Status Indicator | Items and Services Packaged into APC Rates | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | T1H - Lab tests - other (non-Medicare fee schedule) | MUE | Not applicable/unspecified. | CCS Clinical Classification | 233 - Laboratory - Chemistry and Hematology |
Get instant expert-level medical coding assistance.